Search research articles
Contact Us
Filters
Showing results (61-70 of 155) with videos related to
Page
of 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
August 1, 2021
The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy
Conny Vrieling, Samson Y Assele, Lotte Moser, et al.
European Urology
|
October 24, 2003
Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study
Walter Albrecht, Laurence Collette, Cesare Fava, et al.
The Prostate
|
December 31, 2013
One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach?
Vasiliki Pasoglou, Ahmed Larbi, Laurence Collette, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
October 3, 2006
Quality assurance in the EORTC randomized trial 22922/10925 investigating the role of irradiation of the internal mammary and medial supraclavicular lymph node chain works
Philip Poortmans, Vassilis Kouloulias, Geertjan van Tienhoven, et al.
European Urology
|
February 28, 2012
Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
Frédéric E Lecouvet, Jawad El Mouedden, Laurence Collette, et al.
European Urology
|
August 13, 2013
Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up
Urs E Studer, Peter Whelan, Florian Wimpissinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2006
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891
Urs E Studer, Peter Whelan, Walter Albrecht, et al.
European Urology
|
January 15, 2008
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)
Urs E Studer, Laurence Collette, Peter Whelan, et al.
European Urology
|
March 26, 2004
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892
Fritz H Schröder, Peter Whelan, Theo M de Reijke, et al.
Journal of Cellular and Molecular Medicine
|
July 16, 2009
EORTC trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial
Andrea Wittig, Laurence Collette, Klaas Appelman, et al.
Page
of 16
Search research articles
Search
Showing results (61-70 of 155) with videos related to
Sort By:
Page
of 16
European Journal of Cancer (Oxford, England : 1990)
|
August 1, 2021
The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy
Conny Vrieling, Samson Y Assele, Lotte Moser, et al.
European Urology
|
October 24, 2003
Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study
Walter Albrecht, Laurence Collette, Cesare Fava, et al.
The Prostate
|
December 31, 2013
One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach?
Vasiliki Pasoglou, Ahmed Larbi, Laurence Collette, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
October 3, 2006
Quality assurance in the EORTC randomized trial 22922/10925 investigating the role of irradiation of the internal mammary and medial supraclavicular lymph node chain works
Philip Poortmans, Vassilis Kouloulias, Geertjan van Tienhoven, et al.
European Urology
|
February 28, 2012
Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
Frédéric E Lecouvet, Jawad El Mouedden, Laurence Collette, et al.
European Urology
|
August 13, 2013
Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up
Urs E Studer, Peter Whelan, Florian Wimpissinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2006
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891
Urs E Studer, Peter Whelan, Walter Albrecht, et al.
European Urology
|
January 15, 2008
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)
Urs E Studer, Laurence Collette, Peter Whelan, et al.
European Urology
|
March 26, 2004
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892
Fritz H Schröder, Peter Whelan, Theo M de Reijke, et al.
Journal of Cellular and Molecular Medicine
|
July 16, 2009
EORTC trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial
Andrea Wittig, Laurence Collette, Klaas Appelman, et al.
Page
of 16